Shakib Al Hasan diagnosed with retinal condition in left eye
Bangladesh captain Shakib Al Hasan has been diagnosed with a retinal condition in his left eye. This revelation comes after the player reported issues with his visual functions. Reportedly, Shakib went to Singapore for his treatment.
In a press release, Bangladesh Cricket Board (BCB) Senior Physician Dr. Debashis Chowdhury said: "Shakib has been complaining of subtle issues with his left eye. After consulting Ophthalmologists in Bangladesh and abroad and after multiple eye assessments, it was confirmed that he is suffering from Extrafoveal Central Serous Chorioretinopathy (CSR) of the left eye. It has been decided that a conservative approach will be adopted for managing the issue for now."
Extrafoveal Central Serous Chorioretinopathy is a condition that affects the retina, leading to visual disturbances. The medical team overseeing Shakib's case is optimistic about managing the condition effectively with a conservative approach.”
Shakib Al Hasan has been suffering since last year's ODI World Cup
The top-ranked T20I all-rounder has faced persistent injury setbacks since the conclusion of last year's World Cup. He incurred a finger injury, forcing him to withdraw from participation before Bangladesh's final World Cup game. With the goal of making a comeback to the field, he targeted participation in Bangladesh's domestic T20 tournament in January and aimed to secure a spot in the 2024 T20 World Cup squad.
ALSO READ: Harsha Bhogle unsure of England's playing XI for 1st Test
Unfortunately, Shakib had to withdraw from the ongoing Bangladesh Premier League (BPL 2024) due to the eye problem. After playing just one match for Rangpur Riders, he had to leave to seek medical treatment abroad.
The BCB has urged the cricketing fraternity and fans to respect Shakib's privacy as he focuses on his health and recovery. Further updates on his condition will be provided in due course.
For more updates, follow CricXtasy on Facebook, Instagram, Twitter, Telegram and YouTube.